Bath & Body Works, Inc. (NYSE:BBWI) Receives $22.00 Average Price Target from Brokerages

Shares of Bath & Body Works, Inc. (NYSE:BBWI) have received an average rating of “Hold” from the eighteen analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, fourteen have issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $22.00.

BBWI has been the subject of a number of research reports. Piper Sandler began coverage on Bath & Body Works in a research note on Friday, May 15th. They issued a “neutral” rating and a $20.00 price target for the company. Barclays cut their price objective on Bath & Body Works from $25.00 to $23.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 28th. UBS Group reduced their target price on Bath & Body Works from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, May 20th. Telsey Advisory Group lowered their price target on Bath & Body Works from $25.00 to $22.00 and set a “market perform” rating for the company in a report on Thursday, May 28th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $22.00 price target on shares of Bath & Body Works in a report on Monday, July 6th.

Bath & Body Works Trading Down 1.2%

Shares of NYSE:BBWI opened at $20.27 on Friday. The firm has a market cap of $4.08 billion, a PE ratio of 5.69, a price-to-earnings-growth ratio of 2.03 and a beta of 1.38. The company has a fifty day simple moving average of $19.71 and a 200 day simple moving average of $20.45. Bath & Body Works has a 12-month low of $14.27 and a 12-month high of $33.67.

Bath & Body Works (NYSE:BBWI) last posted its quarterly earnings data on Wednesday, May 27th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.03. The firm had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $1.36 billion. Bath & Body Works had a net margin of 10.03% and a negative return on equity of 45.34%. The firm’s revenue was down 3.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.49 EPS. Bath & Body Works has set its Q2 2026 guidance at 0.300-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. As a group, equities research analysts forecast that Bath & Body Works will post 2.63 EPS for the current fiscal year.

Bath & Body Works Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 19th. Shareholders of record on Friday, June 5th were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend was Friday, June 5th. Bath & Body Works’s payout ratio is currently 22.47%.

Institutional Trading of Bath & Body Works

A number of institutional investors and hedge funds have recently modified their holdings of BBWI. Royal Bank of Canada boosted its holdings in shares of Bath & Body Works by 92.8% in the 1st quarter. Royal Bank of Canada now owns 59,877 shares of the company’s stock valued at $1,815,000 after buying an additional 28,815 shares during the period. Goldman Sachs Group Inc. raised its stake in Bath & Body Works by 15.7% during the first quarter. Goldman Sachs Group Inc. now owns 645,970 shares of the company’s stock worth $19,586,000 after acquiring an additional 87,529 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Bath & Body Works by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 562,757 shares of the company’s stock worth $17,063,000 after acquiring an additional 36,684 shares during the last quarter. Intech Investment Management LLC bought a new position in Bath & Body Works in the first quarter worth about $1,155,000. Finally, Geneos Wealth Management Inc. boosted its stake in Bath & Body Works by 217.7% in the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock valued at $35,000 after acquiring an additional 801 shares during the period. 95.14% of the stock is owned by institutional investors and hedge funds.

About Bath & Body Works

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.